Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Rhea-AI Summary
Cadrenal Therapeutics (Nasdaq: CVKD) outlined a consolidated multi-indication strategy for its Cardiac Acute Critical Care franchise centered on CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).
Following the discontinuation of a competitor’s late-stage Phase 3 CSA-AKI trial for lack of efficacy, the company is positioning CAD-1005, a 12-lipoxygenase (12-LOX) inhibitor, for first-in-class potential in the $1 billion+ U.S. CSA-AKI market. CAD-1005 is being studied as a “post-operative shield” intended to reduce platelet hyperactivation in HIT and inflammation-driven injury in CSA-AKI. Late-breaking Phase 2 data presented at ISTH 2026 showed an absolute reduction in thrombotic events greater than 25% with a favorable safety and renal-protective baseline. Cadrenal is pursuing global strategic partnerships, including out-licensing or co-development, for this Phase 3-ready critical care asset.
Positive
- Phase 2 thrombotic event reduction >25% with favorable safety and renal baseline
- $1 billion+ U.S. CSA-AKI market opportunity targeted with CAD-1005
- Phase 3-ready CAD-1005 positioned as first-in-class 12-LOX inhibitor for CSA-AKI and HIT
Negative
- None.
Market Reaction – CVKD
Following this news, CVKD has declined 0.48%, reflecting a mild negative market reaction. The stock is currently trading at $2.09.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 13 | Phase 2 clinical data | Positive | -16.3% | CAD-1005 reported greater than 25% thrombotic-event reduction in HIT |
| Jun 24 | Phase 2 presentation | Positive | -2.6% | CAD-1005 Phase 2 data received late-breaking oral presentation selection |
| Jun 03 | Partnering event | Positive | -3.7% | Cadrenal planned partnering meetings for Phase 3-ready CAD-1005 |
| Apr 30 | FDA Phase 3 path | Positive | +19.3% | FDA meeting supported a pivotal Phase 3 registration trial for CAD-1005 |
| Feb 24 | Phase 2 clinical data | Positive | +16.1% | Phase 2 results showed greater than 25% thrombotic-event reduction |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record was mixed: positive clinical-trial announcements aligned twice and diverged three times, including a -16.26% move after July 13 data.
Key Terms
12-lox medical
heparin-induced thrombocytopenia medical
cardiac surgery-associated acute kidney injury medical
out-licensing financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injury
- Dual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
- Addresses High-Value Gap in the Acute Care Market –First-in-class positioning in the
$1 billion + U.S. CSA-AKI market following the recent discontinuation of a competitor's late-stage Phase 3 clinical trial for lack of efficacy - Global Partnering Potential – Leverages shared in-hospital ICU infrastructure and intravenous (IV) presentation to deliver a critical care asset package
PONTE VEDRA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced a consolidation of its multi-indication strategy for its Cardiac Acute Critical Care (CACC) Franchise, with a focus on CAD-1005 for both HIT and CSA-AKI.
Following a competitor’s recent Phase 3 failure in CSA-AKI, Cadrenal is highlighting the potential of its 12-LOX inhibitor to address a
"The recent clinical failure of a competing late-stage mechanism highlights the urgent need for novel upstream targets, such as 12-LOX, that address the root causes of cardio-renal injury," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “This trial termination underscores the ongoing clinical challenge of identifying targeted pharmacologic strategies for the treatment of CSA-AKI, as no single drug class has yet demonstrated clear preventive efficacy for the condition. The company is actively pursuing strategic partnerships, including out-licensing or co-development, to leverage its transaction-ready, Phase 3-ready asset.
About CAD-1005
CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) and orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also being evaluated for chronic indications. To view how CAD-1005 is intended to work in patients with HIT, visit https://vimeo.com/1209382706/7dde06dc08?share=copy&fl=sv&fe=ci
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. Its lead program, CAD-1005, is being investigated as a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder, and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The Company’s Cardiac Acute Critical Care (CACC) portfolio also includes frunexian, an investigational intravenous Factor XIa inhibitor intended to provide anticoagulation for patients undergoing major cardiac surgery.
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and atrial fibrillation, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. The Company recently submitted a request for Rare Pediatric Disease Designation (RPDD) to the FDA for tecarfarin for “Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Disease”. Tecarfarin has also received Orphan Drug and Fast Track designations from the FDA.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include, without limitation, statements such as the ability of the Company’s Cardiac Acute Critical Care Franchise to address a crucial unmet need; the Company leveraging shared in-hospital ICU infrastructure and identical intravenous (IV) formulations to deliver a critical care asset package; the Company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions; the potential of CAD-1005 to address a
For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.
For more information, please contact:
Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700, CVKD@lythampartners.com
